Partner with us.
Advance medicine.
Our core principles.
- 01
Bioengineering as the platform anchor, not an adjacent discipline.
- 02
Multi-jurisdiction by design, aligned to the policy environment.
- 03
Integrated R&D, manufacturing, and consulting under one corporate roof.
- 04
A platform being built deliberately, with early capital shaping the configuration.
Three areas of business. Five business activities.
- Pharmaceutical and healthcare drug manufacturing and distribution.
- Technical testing and analysis.
- Research and experimental development on biotechnology.
- Bioengineering design activities for the healthcare and medical industry.
- Medical and engineering related scientific and technical consulting.
- Pharmaceuticals Drug development, fill-finish, distribution, and supply. The commercial channel through which the platform's science reaches patients and clinicians.
- Bioengineering Central pillar. Platform development across expression, delivery, and biomanufacturing process engineering. The discipline on which Alifarc's therapeutic and product candidates are intended to be built.
- Biotechnology R&D function focused on translating bioengineering platform capability into specific therapeutic candidates across the focus areas disclosed in the data room.
Founder-led.
Twenty-five years across drug discovery, engineering, finance, and operational leadership, with sustained contributions to medicine and pharmaceuticals. He leads Alifarc's strategy, scientific direction, and corporate development across the United Kingdom, Germany, and Nigeria.
Full leadership teamStrategic partners.
Healthcare-focused venture capital and strategic corporate investors considering seed-to-Series-A engagement. Open to lead and co-lead positions, and to strategic capital from established pharmaceutical and biotechnology corporates with aligned therapeutic-area or platform interest.
Translational research groups, academic medical centres, and biotech platform companies in bioengineering, expression and delivery, and adjacent capability areas. Open to joint research programmes, exclusive licensing, and equity-backed collaboration structures.
Contract development manufacturing organisations (CDMOs), regional distribution partners, and regulatory consultancies in the UK, EU, Africa, and adjacent markets, particularly partners with experience in African market entry and multi-jurisdiction navigation.
Grant-making bodies, foundations, and bilateral or multilateral health-financing institutions whose remit aligns with African pharmaceutical manufacturing capacity, EU critical medicines security, or specific therapeutic priorities. Currently open to early-stage engagement.
Request the
investor data room.
Available to qualified institutional investors and partners.
Request received.
Thank you. We will respond to qualified parties shortly, at the email you provided.